STAT+: Pharmalittle: We’re Reading About a Purdue Pharma Settlement, a Setback for Merck and Eisai, and More
Pfizer executive Andrew Baum, a former Citibank analyst who joined in June 2024, has left his EVP and chief strategy role but will stay on as an adviser to CEO Albert Bourla through the end of the year. His departure highlights a trend of big‑pharma firms hiring ex‑bank analysts to steer strategy and innovation. Meanwhile, a U.S. judge is expected to order Purdue Pharma to forfeit $225 million, clearing the path for a settlement that obligates the Sackler family to pay up to $7 billion to governments and victims. The settlement could become effective on May 1, ending thousands of opioid lawsuits.
Sun Pharma’s ‘Heart Ke Liye 8’ Campaign Crosses 24.1 Million Views
Sun Pharmaceutical Industries’ "Heart ke Liye 8 – Making India Heart Strong" campaign has amassed 24.1 million views since its February launch, leveraging YouTube, Meta, connected TV and health‑tech platforms to promote eight daily habits for cardiovascular wellness. The initiative dovetails...
Merck, Eisai’s Keytruda Triplet Fails to Improve Survival in Kidney Cancer
Merck and Eisai announced that their Phase 3 LITESPARK‑012 trial of a three‑drug regimen—Keytruda, Welireg and Lenvima—failed to improve overall survival or progression‑free survival in first‑line renal cell carcinoma. The control arm received the approved Keytruda‑Lenvima doublet, which also did not...
Revenue Isn’t the Signal: What Early-Stage Health Tech Investors Should Be Watching Instead
Claire Smith of SpringTide Ventures argues that early‑stage health‑tech investors should look beyond headline revenue. She emphasizes customer adoption, sales motion, and scalability within regulated systems as stronger predictors of success. Early contracts may be modest but valuable if they...
SaNOtize - 727784 - 04/17/2026
The U.S. Food and Drug Administration issued a warning letter to SaNOtize, the maker of “NOWONDER™ Nasal Cleanser,” on April 17, 2026. The agency determined the product is an unapproved new drug because its labeling and website claim nitric‑oxide‑based immune benefits, violating sections 505(a)...
Pro Numb Tattoo Numbing Spray, LLC - 722589 - 04/14/2026
The FDA issued a warning letter to Pro Numb Tattoo Numbing Spray, LLC for multiple Current Good Manufacturing Practice (CGMP) violations, including failure to test finished drug batches, inadequate raw‑material verification, and lack of stability data. The firm also marketed...
Where Utah’s Experiment with AI Doctors Is Headed Next
Utah has launched a regulatory sandbox that lets AI-driven health platforms prescribe medications under physician oversight, a move that bypasses typical federal restrictions. The state allocated roughly $5 million to attract startups such as Babylon Health and AIMD for pilot programs...
Neolaia Synthesizes New CD38 Inhibitors
Biohaven disclosed detailed preclinical data on BHV‑2100, a TRPM3 calcium‑channel modulator aimed at neuropathic pain. A new meta‑analysis concluded that anti‑amyloid therapies for Alzheimer’s have not demonstrated clinically meaningful benefits, intensifying debate over the approach. Jiangsu and Shanghai Hengrui patented...
ConcertAI Launches Cadence Suite to Accelerate Patient Access to Life-Changing Therapies
ConcertAI has launched Cadence Suite, an AI-native platform for pharma commercial and field teams to proactively identify and resolve patient access barriers. The suite unifies specialty pharmacy, claims, and social determinants of health data into a single view, enabling real‑time...
Insurance-Provided Grocery Assistance and Health Care Outcomes Among Patients With Diabetes
A new low‑premium health plan from Elevance Health that includes a $1,200‑$3,000 annual grocery benefit was offered to income‑eligible members with type 2 diabetes. Using a doubly robust difference‑in‑differences design, researchers compared 411 members who enrolled with 961 eligible non‑enrollees. The...
What New Atopic Dermatitis Treatments Are in the Pipeline in 2026?
The atopic dermatitis pipeline in 2026 is dominated by next‑generation biologics and selective small molecules that aim to improve efficacy while reducing side‑effects. Connect Biopharma’s rademikibart achieved near‑complete skin clearance in a phase 3 trial, and Apogee’s extended‑half‑life zumilokibart showed durable...
Incyte Discloses New TYK2 And/Or JAK1 Inhibitors
Incyte announced the discovery of a new series of small‑molecule inhibitors that selectively target TYK2 and JAK1, two kinases central to cytokine signaling in autoimmune disorders. The compounds demonstrated sub‑nanomolar potency in cell‑based assays and favorable safety margins in early...
Peer Supervision: A Model for Enhanced Vocational and Emotional Support
A New York community health agency launched a Peer Supervision and Support Work Group to address rising instability among its peer workforce, including housing loss and substance‑use relapse. The initiative introduced three core programs—Enhanced Orientation, Life Skills Group, and Vocational...
Peering In: A Look at Mental Health Peer Providers and How They Help People Recover
Emily Grossman, a recovered bipolar II patient, became a certified peer specialist after traditional routes proved too costly. She now works in community mental health centers and runs her own practice, training clinicians on recovery‑oriented, person‑centered care. The article argues...
Addiction Recovery: The Role of Peer and Alumni Support
Addiction treatment programs are increasingly adding peer‑support and alumni networks to smooth the high‑risk transition from residential care to everyday life. Peer support delivers nonclinical, lived‑experience guidance, while alumni groups offer structured check‑ins, social reinforcement, and resource navigation. Evidence shows...
How Psychiatric Office Support Directly Improves Mental Health Treatment Outcomes
Serenity Mental Health Centers highlights how patient‑centered psychiatric care—anchored by robust office support—directly lifts treatment outcomes. By assigning each patient a team of seven or more staff, from care coordinators to psychiatrists, the clinic creates a strong therapeutic alliance that...
Strengthening Peer Services Through Partnership
The peer‑delivered workforce in behavioral health has surged, with more than 100,000 individuals now certified as peer providers, according to a 2024 Peer Recovery Center of Excellence report. Peer professionals are now embedded across crisis services, hospitals, outpatient programs, housing...
Integrating Peers in CCBHCs: The Power of Lived Experience
Certified Community Behavioral Health Clinics (CCBHCs) are expanding a person‑centered model that bundles mental health, substance‑use treatment, case management, and physical health services. Peer Navigators and Peer Specialists are being woven into these multidisciplinary teams to bring lived‑experience insight and...
From Access to Engagement: Reimagining the Consumer Experience in Behavioral Health
Behavioral health providers have expanded access through telehealth, portals, and peer services, yet consumer engagement remains weak. Recent surveys of providers and patients reveal that cumbersome intake processes and limited post‑visit interaction cause drop‑off during the critical early weeks of...
Pharma Exporters Facing Issues with Online National Drug Licensing System
Indian pharmaceutical exporters are encountering technical problems with the Online National Drug Licensing System (ONDLS), which issues Certificates of Pharmaceutical Products (COPP) under the WHO Good Manufacturing Practices scheme. The Pharmaceuticals Export Promotion Council (Pharmexcil) has launched a feedback drive...
Labor to Tackle Two of Budget’s Biggest Headaches – Aged Care and NDIS – in One Go
Health Minister Mark Butler will announce a $1 bn AUD (≈$660 m USD) boost to aged‑care home‑care packages, fully funding showering, dressing and continence services for about 350,000 seniors. The same pre‑budget speech will unveil a sweeping overhaul of the $50 bn AUD...
Biocon Receives Health Canada Approval for Bosaya and Vevzuo (Biosimilars, Prolia and Xgeva)
Biocon has secured a Notice of Compliance from Health Canada for its denosumab biosimilars, Bosaya and Vevzuo, which mirror Amgen’s Prolia and Xgeva. The approval follows a comprehensive data package demonstrating comparable quality, safety and efficacy to the reference products....
EMI Filter for High-Field MRI Systems and Sensitive Imaging Processes From EMIS
EMIS has launched the MF420-2CF-M MRI filter, a specialized EMI/RFI filter for high‑field MRI suites. The filter delivers attenuation up to 10 GHz, protecting power and data lines entering shielded rooms. Its design features threaded conduit connections, a discharge bleeder resistor,...
How to Speed Up Your Root Canal Recovery
Root canal treatments succeed in over 95% of cases, but recovery experiences vary widely. The healing process unfolds in three phases—immediate (24‑48 hours), intermediate (days 3‑7), and final (weeks 2‑4)—each with distinct symptoms and care needs. Effective pain control with ibuprofen, ice, and...
This Biotech Firm Has Room to Run Despite Surging Nearly 500% in Past Year, Morgan Stanley Says
Arrowhead Pharmaceuticals’ stock has rocketed 473% over the past year, prompting Morgan Stanley to upgrade the shares to overweight and lift its price target to $100 from $78, indicating roughly a 44% upside. The firm is set to release Phase‑3...
Unmet Needs and Key Takeaways for Community Oncologists
Community oncologists face unresolved questions in prostate cancer treatment, especially the optimal sequencing of chemotherapy with androgen‑receptor pathway inhibitors (ARPIs) added to ADT. Existing trials such as ARCHES and PEACE‑1 were designed around ARPI‑plus‑docetaxel, leaving uncertainty about the benefit of...
Advancing in Modern Healthcare: Why DNP Education Is Gaining Attention
Advanced nursing education, especially Doctor of Nursing Practice (DNP) programs, is gaining momentum as health systems adopt digital tools and data‑driven care. Enrollment in DNP programs has risen sharply, reflecting demand for leaders who can translate research into practice. Flexible...
Medicare: CMS’s Use of Data Analytics to Identify and Prevent Fraud
The Centers for Medicare & Medicaid Services (CMS) is leveraging data analytics to detect and stop Medicare fraud, focusing on anomalous billing patterns and spikes. Using these tools, CMS suspended payments and revoked enrollment for 15 providers tied to a...
Peer Support Boosts Reproductive Agency Where Vouchers Fall Short
In rural Uttar Pradesh, a randomized trial of 671 married women compared a personal family‑planning voucher with a “Bring‑a‑Friend” (BAF) voucher that also offered peer support. Both vouchers increased clinic visits, but only the BAF design raised modern contraceptive use...
Selecting Patients for Immunotherapy in CSCC: Key Considerations
Cutaneous squamous cell carcinoma (CSCC) treatment is shifting toward earlier use of systemic immunotherapy, especially for moderate‑risk tumors that are still resectable. Dr. Vishal Patel of George Washington Cancer Center urges clinicians to evaluate checkpoint inhibitors alongside surgery, guided by...
PSMA PET and the Evolving Imaging Landscape in Prostate Cancer
In the 2026 prostate cancer guidelines, PSMA‑PET is elevated to an indispensable imaging tool, expanding beyond initial staging of unfavorable intermediate‑risk and higher‑risk disease to cover biochemical recurrence, including second recurrences. The modality now informs decisions on oligometastatic identification for...
Rethinking When to Start Long-Acting HIV Therapy
Real‑world data from the OPERA cohort of over 5,000 patients show that starting long‑acting cabotegravir plus rilpivirine (CAB+RPV LA) in individuals with detectable viral loads—about 11% above 50 copies/mL—can still achieve virologic suppression comparable to patients who begin treatment already...
The Future of Psoriasis Management: Integration, Innovation, and Holistic Care
Psoriasis management has shifted from modest skin improvement to aiming for complete clearance, driven by a growing arsenal of topicals, biologics, and emerging oral IL‑23 inhibitors. Real‑world data from the Winter Clinical Hawaii 2026 conference show higher persistence with biologics among...
Dr-Julian to Provide Online Mental Health Platform for North East and North Cumbria
Dr-Julian has secured funding from the NHS North East and North Cumbria Integrated Care Board to launch a 24/7 online mental health platform. The initiative is part of the region’s £19 million (≈$24 million) WorkWell programme aimed at reducing unemployment caused by...
Monopar Therapeutics Reports P-III (FoCus) Trial Data on ALXN1840 in Wilson Disease
Monopar Therapeutics reported Phase III FoCus trial results for ALXN1840, an oral copper‑binding agent, in Wilson disease patients with neurologic involvement. The study enrolled 77 patients on ALXN1840 and 35 on standard of care, showing neurologic worsening in only 9% versus...
The Hidden Cost of IV Fluid Shortages on Outpatient Facilities: What the Data Shows
The 2024‑2025 IV fluid shortage, sparked by Hurricane Helene’s damage to Baxter’s North Cove plant, has spilled over from hospitals to thousands of outpatient facilities such as infusion centers, ambulatory surgery centers, pain clinics, and oncology practices. While hospitals can...
STAT+: Tortugas Neuroscience Launches with Hopes to Develop Drugs for Brain Disorders, Other Conditions
Tortugas Neuroscience launched with a $106 million financing round led by Cure Ventures, The Column Group and AN Ventures. The startup has licensed two schizophrenia and tinnitus candidates from China’s Jiangsu Hansoh and two additional therapies for focal epilepsy and encephalopathies...
Fluoride In Drinking Water Not Linked to Lower IQ
A new longitudinal study of 10,317 Wisconsinites spanning 1957‑2021 found no link between community water fluoridation and lower IQ or cognitive decline. The research directly challenges a 2025 paper that reported IQ reductions at fluoride concentrations far exceeding typical U.S....
Merck-Eisai’s Kidney Cancer Drug Combo Fail to Improve Survival in Late-Stage Trial
Merck and Eisai reported that their late‑stage trial of Keytruda plus Lenvima with Welireg, as well as a Lenvima‑MK‑1308A combo, failed to improve overall survival or progression‑free survival in clear cell renal cell carcinoma. The study enrolled 1,688 patients and...
NB Corp. Of America Plans Live Demos This Week
NB Corp. of America will showcase live demonstrations of its NV Slide Way configuration and the 3‑axis BG Actuator at the MD&M South trade show, Booth #2311 Automation. The Slide Way delivers precise linear motion without the need for a...
Avricore Health Achieves Milestones and Outlines UK Expansion Roadmap for HealthTab™ Platform
Avricore Health announced that its HealthTab point‑of‑care platform screened over 3,500 patients in community pharmacies across North East and North Central London, completing 2,295 HbA1c tests at 57 locations in a single month. The company unveiled "The Path Forward" roadmap,...
Akeso Announces P-II (COMPASSION-26) Trial Results on Cadonilimab + CT in 1L PDAC
Akeso reported Phase II COMPASSION‑26 data showing its bispecific antibody cadonilimab combined with chemotherapy as a first‑line option for advanced pancreatic ductal adenocarcinoma. With a median progression‑free survival of 11.1 months and median overall survival exceeding 23 months, the regimen delivered 12‑month and...
How the Depo-Provera Brain Tumor Lawsuit Works
The Depo‑Provera brain tumor lawsuit alleges that the contraceptive shot’s manufacturer failed to warn users of an increased risk of meningiomas, a type of brain or spinal‑cord tumor. Plaintiffs must demonstrate a causal link through medical records, expert testimony, and...
Preventive Healthcare Startup CENT Opens Flagship Clinic in Bengaluru
Preventive healthcare startup CENT, founded by Practo’s Shashank ND, opened its first 7,000‑sq‑ft flagship prevention centre in Bengaluru. The centre offers a single‑purpose AI‑driven screening protocol—CCNM—combining whole‑body MRI, ultra‑low‑dose cardiac CT, DEXA, ECG and over 120 biomarker tests, delivering a...
Alamar Lists on Nasdaq, Giving Qiming Its Fifth IPO in 2026
Alamar Biosciences, a proteomics company founded in 2018, debuted on Nasdaq, delivering Qiming Venture Partners its fifth IPO in 2026. The firm’s Nulisa technology provides femtogram‑level sensitivity and a 12‑log dynamic range, while its Argo HT instrument has installed over 100...
NHS ‘at Risk of Collapse’ without More Focus on Diversity
A joint study by UCL and the University of Leicester warns that the NHS could collapse without a focused strategy to retain ethnically diverse staff, especially international workers. Surveys from 2021‑2024 show staff turnover intentions rising from 30% to 47%,...
UnitedHealth Group Profits Eclipse $6 Billion As Medical Costs Ease
UnitedHealth Group lifted its full‑year 2026 earnings outlook to more than $17.35 per share after reporting first‑quarter net income of $6.3 billion. The medical loss ratio improved to 83.9% from 84.8% a year earlier, reflecting tighter cost management and favorable reserve...
Why Aspirin Is Becoming a Weapon Against Cancer
Aspirin, the 4,000‑year‑old painkiller, is now shown to cut colorectal cancer risk in high‑genetic‑risk patients. A 10‑year trial of 861 Lynch‑syndrome participants found a daily 600 mg dose halved cancer incidence, and a lower 75‑100 mg dose appears equally effective. The UK...
Tom Brady's New Play: Making GLP-1s Affordable for Healthcare Workers
Tom Brady, co‑owner of eMed, is launching an employer‑subsidized GLP‑1 program aimed at U.S. healthcare workers. Employers pay a fixed $25 per employee each month, while employees cover $99 for medication and 24/7 clinical support. eMed reports participants lose an...
New Blood Test Aims to Spot Liver Scarring Before It Paves the Way to Cancer
Researchers at Johns Hopkins have developed a blood test that analyzes cell‑free DNA fragments with a machine‑learning model to identify early‑stage liver fibrosis, a reversible precursor to cirrhosis and liver cancer. In a study of 423 participants, the assay detected...